These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17850173)

  • 1. Biological treatments for amfetamine dependence : recent progress.
    Hill KP; Sofuoglu M
    CNS Drugs; 2007; 21(10):851-69. PubMed ID: 17850173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of naltrexone for amfetamine and methamfetamine use disorder: a systematic review of randomized controlled trials.
    Lam L; Anand S; Li X; Tse ML; Zhao JX; Chan EW
    Clin Toxicol (Phila); 2019 Apr; 57(4):225-233. PubMed ID: 30451013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genes and molecules that can potentiate or attenuate psychostimulant dependence: relevance of data from animal models to human addiction.
    Niwa M; Yan Y; Nabeshima T
    Ann N Y Acad Sci; 2008 Oct; 1141():76-95. PubMed ID: 18991952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.
    de la Torre R; Farré M; Navarro M; Pacifici R; Zuccaro P; Pichini S
    Clin Pharmacokinet; 2004; 43(3):157-85. PubMed ID: 14871155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy with reboxetine in amphetamine withdrawal syndrome.
    Molina JD; de Pablo S; López-Muñoz F; Alamo C; Blasco-Fontecilla H; González-Parra S
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1353-5. PubMed ID: 16631296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinil.
    Heal DJ; Buckley NW; Gosden J; Slater N; France CP; Hackett D
    Neuropharmacology; 2013 Oct; 73():348-58. PubMed ID: 23748096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lisdexamfetamine and immediate release d-amfetamine - differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity.
    Rowley HL; Kulkarni R; Gosden J; Brammer R; Hackett D; Heal DJ
    Neuropharmacology; 2012 Nov; 63(6):1064-74. PubMed ID: 22796358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapeutic agents in the treatment of methamphetamine dependence.
    Morley KC; Cornish JL; Faingold A; Wood K; Haber PS
    Expert Opin Investig Drugs; 2017 May; 26(5):563-578. PubMed ID: 28351169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Substitution therapy tested against amphetamine dependence].
    Bloniecki Kallio V; Guterstam J; Franck J
    Lakartidningen; 2016 Jan; 113():. PubMed ID: 26756343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuation of d-amphetamine self-administration by baclofen in the rat: behavioral and neurochemical correlates.
    Brebner K; Ahn S; Phillips AG
    Psychopharmacology (Berl); 2005 Feb; 177(4):409-17. PubMed ID: 15630589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No association between CART (cocaine- and amphetamine-regulated transcript) gene and methamphetamine dependence.
    Morio A; Ujike H; Nomura A; Tanaka Y; Morita Y; Otani K; Kishimoto M; Harano M; Inada T; Komiyama T; Yamada M; Sekine Y; Iwata N; Iyo M; Sora I; Ozaki N; Kuroda S
    Ann N Y Acad Sci; 2006 Aug; 1074():411-7. PubMed ID: 17105939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whizz-dick: side effect, urban myth or amfetamine-related koro-like syndrome?
    Bloor RN
    Int J Clin Pract; 2004 Jul; 58(7):717-9. PubMed ID: 15311730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agents in development for the management of cocaine abuse.
    Gorelick DA; Gardner EL; Xi ZX
    Drugs; 2004; 64(14):1547-73. PubMed ID: 15233592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress and prospects in pharmacogenetics of antidepressant drugs.
    Fabbri C; Crisafulli C; Calabrò M; Spina E; Serretti A
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1157-68. PubMed ID: 27310483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WITHDRAWN: Treatment for amphetamine dependence and abuse.
    Srisurapanont M; Jarusuraisin N; Kittirattanapaiboon P; Kao U
    Cochrane Database Syst Rev; 2014 Apr; (4):CD003022. PubMed ID: 24737554
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacogenetics and treatment response in schizophrenia].
    Moulier V; Januel D
    Encephale; 2007 Dec; 33(6):954-64. PubMed ID: 18789788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence.
    Tiihonen J; Kuoppasalmi K; Föhr J; Tuomola P; Kuikanmäki O; Vorma H; Sokero P; Haukka J; Meririnne E
    Am J Psychiatry; 2007 Jan; 164(1):160-2. PubMed ID: 17202560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction.
    Cao DN; Shi JJ; Hao W; Wu N; Li J
    Eur J Pharmacol; 2016 Jun; 780():129-35. PubMed ID: 27018393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacogenetics and tailored drug treatment in schizophrenia].
    Andreassen OA; Steen VM
    Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2400-2. PubMed ID: 16998555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study.
    Martín-Santos R; Torrens M; Poudevida S; Langohr K; Cuyás E; Pacifici R; Farré M; Pichini S; de la Torre R
    Addict Biol; 2010 Jan; 15(1):15-22. PubMed ID: 19878141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.